RBC Capital Maintains Outperform on Sarepta Therapeutics, Raises Price Target to $150
RBC Capital analyst Brian Abrahams maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Outperform and raises the price target from $145 to $150.
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first two sessions of the holiday-shortened week before making a comeback.
Sarepta Bets On GenEdit’s Nanoparticles’ In $57M Gene Editing Partnership
Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to
Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Lowers Price Target to $71
Morgan Stanley maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and lowers the price target from $92 to $71.
Sarepta Therapeutics, GenEdit Share Progress On Research Collaboration And Announce Agreement To Develop Gene Editing Therapeutics For Neuromuscular Diseases; GenEdit May Receive Up To $57M In Near-term Payments And Is Also Eligible For Future Mileston…
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, and GenEdit, Inc., a developer of genetic medicines that leverage its NanoGalaxyTM polymer nanoparticle platform for
Analyst Ratings For Sarepta Therapeutics
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
Morgan Stanley Maintains Equal-Weight on Sarepta Therapeutics, Raises Price Target to $92
Morgan Stanley maintains Sarepta Therapeutics (NASDAQ:SRPT) with a Equal-Weight and raises the price target from $90 to $92.
The Daily Biotech Pulse: Adagio’s Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
Lysogene Announced Termination of License Agreement With Sarepta for LYS-SAF302 Program, Regaining Global Commercial Rights
Lysogene (FR0013233475 – LYS) (Paris:LYS), a gene therapy platform company targeting central nervous system (CNS) diseases, today announced the termination of its license agreement with Sarepta for LYS-SAF302, a phase 2/3 asset for the treatment of mucopolysaccharidosis Type IIIA (MPS IIIA), effective as of July 11, 2022.
Sarepta Therapeutics Reports Its SRP-9001 Showed Statistically Significant Improvements vs Pre-Specified Matched External Control In Part 2 Of Study
Participants from the placebo crossover group in Part 2 of Study SRP-9001-102 , scored 2.0 points higher on the mean North Star Ambulatory Assessment (NSAA) 48 weeks after treatment with SRP-9001 compared to